08:53 AM EST, 02/27/2025 (MT Newswires) -- Kymera Therapeutics ( KYMR ) reported a Q4 net loss Thursday of $0.88 per diluted share, wider than the loss of $0.25 a year earlier.

Analysts polled by FactSet expected a loss of $0.86.

Collaboration revenue for the quarter ended Dec. 31 was $7.4 million, down from $47.9 million a year earlier.

Analysts surveyed by FactSet expected $14.4 million.

Kymera said that as of Dec. 31, it had about $851 million in cash, cash equivalents, and investments, which it expects to provide a cash runway into mid-2027.